drugset / Trial / NCT02100150
A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of mTBI in adolescents and adults.
Timeline
- Start
- 2014-09
- Primary completion
- 2016-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trofinetide | Peptide | 35 mg/kg | Oral |
| Subject | Trofinetide | Peptide | 70 mg/kg | Oral |